Last $132.53 USD
Change Today -0.15 / -0.11%
Volume 1.8M
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$132.96
Previous Close
$132.68
Day High
$133.01
Day Low
$132.04
52 Week High
08/18/14 - $133.98
52 Week Low
08/22/13 - $104.83
Market Cap
100.7B
Average Volume 10 Days
2.9M
EPS TTM
$6.69
Shares Outstanding
759.6M
EX-Date
08/12/14
P/E TM
19.8x
Dividend
$2.44
Dividend Yield
1.74%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $845.9K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Announces Second Placebo-Controlled Phase 3 Study

Amgen announced that second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30% reduction from baseline in parathyroid hormone (PTH) levels during an Efficacy Assessment Phase (EAP) defined as the period between weeks 20 and 27. These results follow the recent announcement of positive data from a prior placebo-controlled Phase 3 study of AMG 416 which was similar in design and size. In the AMG 416 group, 74.0% of patients achieved a > 30% reduction from baseline in PTH compared with 8.3% in the placebo arm, a statistically significant result. Both of these secondary endpoint results were statistically significant. Treatment-emergent adverse events (TEAEs) were reported in 91.6 and 78.7% of patients who received AMG 416 and placebo, respectively. TEAEs that were reported in > 10% of patients who received AMG 416 included (AMG 416 vs. placebo, respectively): blood calcium decreased (61.0 and 8.3%), nausea (12.4 and 5.1%), muscle spasms (12.0 and 7.1%) and vomiting (10.4 and 7.1%). TEAEs of hypocalcemia (symptomatic) were reported in 7.2% of patients who received AMG 416 versus 0.4% in the placebo group. Serious adverse events (SAEs) were reported in 27.1 and 30.7% of patients who received AMG 416 and placebo, respectively. This was a 26-week, randomized, double-blind, placebo-controlled study (study number 20120229) that evaluated the efficacy and safety of AMG 416 for the treatment of SHPT in 508 patients with CKD receiving hemodialysis. Patients received AMG 416 or placebo three times per week by intravenous injection with each hemodialysis treatment. Doses ranged from a minimum of 2.5 mg to a maximum of 15 mg. Patients also received standard of care which could include calcium supplements, vitamin D sterols and phosphate binders, if prescribed by the individual physician.

Amgen Announces Phase 3 ASPIRE Trial of Kyprolis(R) in Patients with Relapsed Multiple Myeloma Met Primary Endpoint

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc. announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). Patients treated with Kyprolis(R) (carfilzomib) for Injection in combination with Revlimid(R) (lenalidomide) and low-dose dexamethasone (KRd) lived significantly longer without their disease worsening (median 26.3 months) compared to patients treated with Revlimid and low-dose dexamethasone (Rd) (median 17.6 months) (HR=0.690, 95% CI, 0.570, 0.834, p<0.0001). While the data for overall survival, a secondary endpoint, are not yet mature, the analysis showed a trend in favor of KRd that did not reach statistical significance. The safety profile observed in this study is consistent with the current U.S. Kyprolis label, including the rate of cardiac events. Treatment discontinuation due to adverse events and on-study deaths were comparable between the two arms. No new safety signals were identified.

Amgen Inc. Enters into Amended and Restated Revolving Credit Agreement with Citibank, N.A

On July 30, 2014, Amgen Inc. entered into an amended and restated revolving credit agreement with Citibank, N.A., as administrative agent, JPMorgan Chase Bank, N.A., as syndication agent, and the other banks party thereto, for a total commitment of $2.5 billion. Financing under the revolving credit agreement is available for general corporate purposes, including as a liquidity backstop to commercial paper program. The commitments under the revolving credit agreement may be increased by up to $500 million in the aggregate upon request at the discretion of the banks and subject to certain customary requirements. The commitments of each bank under the revolving credit agreement have an initial term of five years and may be extended for up to two additional one year periods upon request at the discretion of the respective bank, subject to certain customary requirements. The revolving credit agreement amends and restates existing revolving credit agreement dated as of December 2, 2011. Advances under the revolving credit agreement will bear interest at an annual rate of, at option, either the applicable LIBOR rate (or EURIBOR rate for certain advances denominated in Euros) plus between 0.690% and 1.300%, depending on the rating of senior long-term unsecured debt or the high of (A) Citibank's base commercial lending rate, (B) the overnight federal funds rate plus 0.50% and (C) one month LIBOR plus 1.00%, plus between 0.000% and 0.300%, depending on the rating of senior long-term unsecured debt. The company agreed to pay a fee for committed funds under the revolving credit agreement, whether used or unused, of between 0.06% and 0.20% per annum depending on the rating of senior long-term unsecured debt. The revolving credit agreement includes a $300 million sub-limit for issuances of letters of credit. The revolving credit agreement contains customary affirmative and negative covenants, including limitations on mergers, consolidations and sales of assets; limitations on liens and sales and leasebacks; limitations on transactions with affiliates and limitations on subsidiary indebtedness. In addition, the revolving credit agreement contains a maximum ratio of total debt to the sum of net worth and total debt, each on a consolidated basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $132.53 USD -0.15

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMGN.
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
No financial data is available for AMGN.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.